• Elisabeth Stögmann and Reinhold Schmidt.
• Department of Neurology, Medical University of Vienna, Waehringer Gürtel 18-20, 1090, Vienna, Austria. elisabeth.stoegmann@meduniwien.ac.at.
• Wien. Klin. Wochenschr. 2024 Nov 6.

AbstractAmyloid-beta (Aβ) antibody treatment has emerged as a promising approach for the treatment of Alzheimer's disease (AD), targeting the accumulation of Aβ plaques, which are a hallmark of the disease. This review provides an update on recent clinical trial data, highlighting the efficacy and safety of various antibodies targeting Aβ. Recent trials have demonstrated that certain Aβ antibodies can reduce amyloid plaques and slow cognitive decline in patients with early AD. Key findings from trials of drugs are discussed, including their mechanisms of action, dosing regimens, and observed side effects. The potential for Aβ antibody therapy to be integrated into routine clinical practice is also explored. While Aβ antibody therapy represents a significant advancement in AD treatment, ongoing research is needed to optimize their use and understand their long-term impact. This review underscores the importance of personalized medicine in AD and the need for continued innovation in therapeutic strategies.© 2024. The Author(s).

5 keywords...

hide…